UPM Institutional Repository

Histopathological insights and therapeutic prospects of MCC950 in diabetes-associated autonomic-related structural alterations in a type 1 diabetes Wistar rat model


Citation

Subramaniam, Shamala Devi and Chupri, Juita and Ahmad Bajari, Zamzarina and Yi, Xin and Abas, Razif (2026) Histopathological insights and therapeutic prospects of MCC950 in diabetes-associated autonomic-related structural alterations in a type 1 diabetes Wistar rat model. Diabetology and Metabolic Syndrome, 18. art. no. 143. pp. 1-13. ISSN 1758-5996

Abstract

Diabetes-Associated Autonomic-Related Structural Alterations (DAAS) is a severe complication of type 1 diabetes mellitus (T1DM) characterized by autonomic nerve fiber dysfunction in the heart and blood vessels. This study aimed to elucidate the histopathological mechanisms underlying DAAS and evaluate the therapeutic potential of MCC950, an NLRP3 inflammasome inhibitor, in a Wistar rat model. Male Wistar rats were divided into control and T1DM groups, with diabetes induced by streptozotocin (STZ) injection. Following confirmation of DAAS through elevated serum noradrenaline levels, diabetic rats were subdivided into positive control (insulin-treated), treatment (MCC950), and untreated groups. The stellate ganglia, thoracic aorta, and left ventricle were dissected for histological examination using Haematoxylin and Eosin (H&E) and Masson Trichrome staining. STZ-induced hyperglycemia was evident by Week 1 and sustained throughout the study. Serum noradrenaline levels significantly increased by Week 14 in diabetic rats, indicating DAAS onset. Histological analysis revealed atrophy in stellate ganglia, endothelial damage in the thoracic aorta, and myocardial fibrosis in untreated diabetic rats. MCC950 treatment preserved ganglionic structure, mitigated vascular damage, and reduced myocardial fibrosis, demonstrating its potential in attenuating DAAS progression. These findings highlight MCC950 as a promising therapeutic agent for DAAS by targeting inflammation and preserving autonomic and cardiovascular function. Further investigations are warranted to validate MCC950’s efficacy in human trials, with the potential to improve clinical outcomes for T1DM patients at risk of DAAS.


Download File

[img] Text
127267.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB)

Additional Metadata

Item Type: Article
Subject: Internal Medicine
Subject: Endocrinology, Diabetes and Metabolism
Divisions: Faculty of Medicine and Health Science
DOI Number: https://doi.org/10.1186/s13098-026-02166-4
Publisher: BioMed Central Ltd
Keywords: Diabetes-associated autonomic-related structural alterations (DAAS); Histopathology; MCC950; NLRP3 inflammasome; Type 1 diabetes mellitus (T1DM)
Sustainable Development Goals (SDGs): SDG 3: Good Health and Well-being, SDG 12: Responsible Consumption and Production, SDG 17: Partnerships for the Goals
Depositing User: Ms. Siti Radziah Mohamed@mahmod
Date Deposited: 22 Jul 2026 05:53
Last Modified: 22 Jul 2026 05:53
Altmetrics: http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.1186/s13098-026-02166-4
URI: http://psasir.upm.edu.my/id/eprint/127267
Statistic Details: View Download Statistic

Actions (login required)

View Item View Item